GLAXO

GlaxoSmithKline Pharmaceuticals Share Price

 

 

Start SIP in GLAXO

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume

Investment Returns

  • Over 1 Month -4.25%
  • Over 3 Month -10.74%
  • Over 6 Month -25.57%
  • Over 1 Year + 5.99%

Smart Investing Starts Here Start SIP with GlaxoSmithKline Pharmaceuticals for Steady Growth!

Invest Now

GlaxoSmithKline Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

GlaxoSmithKline Pharmaceuticals Financials

GlaxoSmithKline Pharmaceuticals Technicals

EMA & SMA

Current Price
₹2,545.60
+ 34.8 (1.39%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹2,535.39
  • 50 Day
  • ₹2,615.66
  • 100 Day
  • ₹2,708.43
  • 200 Day
  • ₹2,727.44

Resistance and Support

2539.77 Pivot Speed
  • R3 2,679.63
  • R2 2,631.07
  • R1 2,588.33
  • S1 2,497.03
  • S2 2,448.47
  • S3 2,405.73

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

GlaxoSmithKline Pharmaceuticals Ltd., based in Mumbai, manufactures and distributes prescription medicines across therapeutic areas like dermatology, diabetes, and cardiovascular diseases. It also offers vaccines for hepatitis, influenza, chickenpox, and other infectious diseases in India and global markets.

Glaxosmithkline Pharms. has an operating revenue of Rs. 3,708.90 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 34% is great, ROE of 47% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 42 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 66 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

GlaxoSmithKline Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-06 Quarterly Results
2025-08-01 Quarterly Results
2025-05-13 Audited Results & Final Dividend
2025-02-14 Quarterly Results (Revised) per share(300%)Dividend
2024-10-29 Quarterly Results & Interim Dividend
Date Purpose Remarks
2025-05-30 FINAL Rs.42.00 per share(420%)Final Dividend
2024-11-07 INTERIM Rs.12.00 per share(120%)Interim Dividend
2024-05-31 FINAL Rs.32.00 per share(320%)Final Dividend
2023-06-30 FINAL Rs.32.00 per share(320%)Final Dividend
2022-07-08 FINAL Rs.30.00 per share(300%)Dividend
View GlaxoSmithKline Pharmaceuticals Dividend History Arrow

GlaxoSmithKline Pharmaceuticals F&O

GlaxoSmithKline Pharmaceuticals Shareholding Pattern

75%
5%
3%
5%
0%
10%
2%

About GlaxoSmithKline Pharmaceuticals

  • NSE Symbol
  • GLAXO
  • BSE Symbol
  • 500660
  • Managing Director
  • Mr. B Akshikar
  • ISIN
  • INE159A01016

Similar Stocks to GlaxoSmithKline Pharmaceuticals

GlaxoSmithKline Pharmaceuticals FAQs

GlaxoSmithKline Pharmaceuticals share price is ₹2,545 As on 06 December, 2025 | 01:00

The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹43124 Cr As on 06 December, 2025 | 01:00

The P/E ratio of GlaxoSmithKline Pharmaceuticals is 45.1 As on 06 December, 2025 | 01:00

The PB ratio of GlaxoSmithKline Pharmaceuticals is 22.1 As on 06 December, 2025 | 01:00

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23